Stocks in play: Appili Therapeutics Inc.
Announced positive one-year challenge results from its preclinical study evaluating the efficacy of biodefense vaccine candidate ATI-1701 in a lethal model of tularemia. A survival rate of 29% (n = 2/7) was reported in the ATI-1701 vaccinated cohort, compared to 0% (n = 0/5) in mock vaccinated controls. Appili Therapeutics Inc. shares T.APLI are trading down $0.01 at $0.19.
Read:
Innovations in Plant-Based Protein Products Supplying the Food Industry’s Strongest Trends
Dogecoin Set to Deliver Long Term, as Major Businesses Make Moves to Accept it as Payment
Crypto Miners Making Gains on Rising Waves for Bitcoin, Ethereum, Dogecoin and More
Hedge-Like Properties of Bitcoin and Other Digital Currencies are Driving Crypto Mining Stocks Up
Shortages of Covid-19 Tests Creates Accelerated Demand for New Diagnostic Technology